On March 8, 2016, Amarin Pharmaceuticals, Inc. (“Amarin”) and the Food and Drug Administration (“FDA” or the “Agency”) reached a settlement agreement in a closely followed case involving Amarin’s First Amendment rights to engage in truthful and non-misleading speech promoting an off-label use of Vascepa®. Amarin and FDA had been engaged in settlement talks since last August, when Judge Engelmayer, in the Southern District of New York, granted a motion for preliminary injunction (PI) in favor of Amarin.
In the August decision, Judge Engelmayer held that FDA may not bring a misbranding action under the Food, Drug & Cosmetic Act (FD&C Act) “based on truthful promotional speech alone, consistent with the First Amendment.” Amarin Pharma, Inc. v. United States Food and Drug Administration, 119 F. Supp. 3d 196, 224 (S.D.N.Y. 2015).
Please see full publication below for more information.